What type of therapy is typically used to reduce morbidity risk in Factor V Leiden?

What type of therapy is typically used to reduce morbidity risk in Factor V Leiden?

• A. Anticoagulant therapy
• B. Aspirin therapy
• C. Thrombolytic therapy
• D. Corticosteroid therapy

Answer: (A)

Anticoagulant therapy is the appropriate choice for reducing morbidity risk in individuals with Factor V Leiden due to its role in preventing venous thromboembolism (VTE), which is a significant risk associated with this genetic mutation. Factor V Leiden increases the risk of abnormal blood clot formation, leading to deep vein thrombosis (DVT) and pulmonary embolism (PE). Anticoagulants work by inhibiting certain factors in the coagulation cascade, effectively reducing the likelihood of clot formation and managing the risks associated with this condition.

In contrast, while aspirin therapy can have some antithrombotic effects, it is not sufficient as a standalone treatment for those with Factor V Leiden who are at high risk of thrombotic events. Thrombolytic therapy is primarily used in acute settings to dissolve clots that have already formed rather than as preventive measures in patients with a predisposition to clotting. Corticosteroid therapy is generally used for inflammation and autoimmune conditions and does not directly address the coagulation issues related to Factor V Leiden. Thus, anticoagulant therapy stands out as a targeted and effective approach to mitigating the risks associated with this condition.